证券日报网讯2月6日，阿特斯在互动平台回答投资者提问时表示，公司会在定期报告中披露各报告期末 的股东人数。根据公司2025年第三季度报告，截至报告期末(2025年9月30日)公司普通股股东总数为 48806户。 ...

证券日报网讯 2月5日，东星医疗在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东总 数为9302户（含信用账户）。 （文章来源：证券日报） ...

格隆汇1月27日丨东星医疗(301290.SZ)公布，预计2025年归属于上市公司股东的净利润-4,500万元 ～-3,200万元，扣除非经常性损益后的净利润-7,200万元～-5,100万元。1、报告期内，受市场竞争加剧 和客户需求放缓的影响，公司吻合器零部件、医疗设备相关业务收入有所下降，致使主营业务整体毛利 较上年同期有所减少；2、根据《企业会计准则第 8 号——资产减值》及相关会计政策规定，基于谨慎 性原则，结合对全资子公司江苏孜航精密五金有限公司 2025 年度及未来经营业绩、盈利能力的分析， 公司对截至 2025 年 12 月 31 日的资产组进行了减值测试。经初步测算，公司预计2025 年度计提商誉减 值准备金额约为 9,790.94 万元，计提无形资产减值准备的金额约为562.92 万元，减值准备金额合计约为 10,353.86 万元。本次业绩预告情况已考虑拟计提资产减值准备对公司净利润的影响。截至本公告披露 日，上述资产减值测试工作尚在进行中，最终资产减值准备计提金额将由公司聘请的具备证券期货从业 资格的评估机构及审计机构进行评估和审计后确定。 ...

证券代码：301290 证券简称：东星医疗 公告编号：2026-003 江苏东星智慧医疗科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 单位：万元 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -4,500 | | ～ | -3,200 | 9,742.48 | | 扣除非经常性损益后的净利润 | -7,200 | | ～ | -5,100 | 6,645.91 | 公司将严格依照有关法律法规的规定和要求，及时做好信息披露工作。敬请广大投资 者谨慎决策，注意投资风险。 五、备查文件 董事会关于本期业绩预告的情况说明。 本次业绩预告情况已考虑拟计提资产减值准备对公司净利润的影响。截至本公告披露 日，上述资产减值测试工作尚在进行中，最终资产减值准备计提金额将由公 ...

融券方面，东星医疗1月26日融券偿还700.00股，融券卖出100.00股，按当日收盘价计算，卖出金额 2870.00元；融券余量5000.00股，融券余额14.35万元，超过近一年90%分位水平，处于高位。 1月26日，东星医疗跌0.42%，成交额4362.35万元。两融数据显示，当日东星医疗获融资买入额291.26 万元，融资偿还1015.30万元，融资净买入-724.04万元。截至1月26日，东星医疗融资融券余额合计 9851.57万元。 融资方面，东星医疗当日融资买入291.26万元。当前融资余额9837.22万元，占流通市值的4.99%，融资 余额超过近一年90%分位水平，处于高位。 分红方面，东星医疗A股上市后累计派现1.69亿元。 责任编辑：小浪快报 资料显示，江苏东星智慧医疗科技股份有限公司位于江苏省常州市武进区长扬路24-4号，成立日期2001 年2月21日，上市日期2022年11月30日，公司主营业务涉及以吻合器为代表的外科手术医疗器械的研 发、生产和销售。主营业务收入构成为：吻合器53.03%，吻合器零配件17.55%，医疗设备15.59%，低 值耗材13.24%，其他0.59%。 截至 ...

证券日报网讯1月26日，东星医疗（301290）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总数为8993户(含信用账户)。 ...

证券代码：301290 证券简称：东星医疗 公告编号：2026-002 江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 2025年11月26日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号：2025-048）。 2025年12月26日，公司披露了《关于筹划重大资产重组的进展公告》（公告编 号：2025-057）。 截至本公告披露之日，公司根据相关规定，委托华泰联合证券有限责任公司担 任本次重大资产重组的独立财务顾问，委托北京市天元律师事务所、厦门嘉学资产 评估房地产估价有限公司、立信会计师事务所（特殊普通合伙）为本次重大资产重 组提供法律、评估、审计服务。公司积极组织各中介机构开展对标的公司的尽职调 查以及审计、评估等工作，并就上述重大资产重组事项同各相关方持续沟通协商。 因财务数据有效期要求，公司及标的公司目前正有序组织相关方对本次交易涉及的 财务数据进行加期审计及更新工作，后续公司亦将按照相关法律法规的规定及时披 露项目进展情况。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"或"上市公司"） 拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝" 或"标 ...

Investment Rating - The report gives a "Buy" rating for Dongxing Medical [5] Core Viewpoints - Dongxing Medical is positioned as a micro-invasive surgical platform company with diversified layouts that promote growth. The company focuses on the anastomosis device industry chain and is gradually expanding into other micro-invasive surgical products, aiming to establish itself as a platform enterprise in medical devices [3][12] - The company plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., which has obtained 58 medical device registration certificates, enhancing its medical device platform and facilitating synergistic development [3][12] - The company has a concentrated shareholding structure and a professional management team, with expected revenue growth driven by product upgrades and cost control [3][12] Summary by Sections 1. Company Overview - Dongxing Medical has diversified its business since its establishment in 2001, transitioning from an agency model to a medical device manufacturer. The company has completed several acquisitions to integrate its supply chain, including the acquisition of Weike Medical and Zihang Precision, which closed the anastomosis device industry chain [12][19] - The company has a strong cash position, with cash and cash equivalents reaching 1.2 billion yuan, supporting future acquisitions [30][32] 2. Anastomosis Device Market - The anastomosis device market in China is expected to reach 9.82 billion yuan by 2024, with a compound annual growth rate (CAGR) of 8.1% from 2019 to 2024. The electric laparoscopic anastomosis device market is projected to grow significantly, with a CAGR of 44.4% during the same period [49][52] - The report indicates that the impact of centralized procurement on pricing has reached a turning point, with price adjustments stabilizing and the industry entering a phase of steady growth as penetration rates increase [54][55] 3. New Surgical Products - The company is expanding its product line to include ultrasonic knives, with a market size in the tens of billions. The domestic market for ultrasonic knives is rapidly increasing due to the rise in domestic production rates [5][12] - The company is also collaborating with Shanghai Jiao Tong University to develop synthetic biological materials, which are expected to be applied in serious medical fields such as hemostasis and scar repair, adding another growth point [5][12] 4. Financial Forecast and Valuation - The company forecasts revenues of 379 million yuan, 445 million yuan, and 512 million yuan for 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be -37 million yuan, 94 million yuan, and 121 million yuan for the same years [5][8] - The report estimates a price-to-earnings (PE) ratio of 29x for 2026 based on the closing price on January 16, 2026 [5][8]

Core Viewpoint - Dongxing Medical (301290.SZ) is currently not involved in the design, research, or production of surgical robot-related products, focusing instead on innovative medical devices such as electric endoscopic staplers, ultrasonic knives, and tissue clips [1] Group 1 - The company's current research and development priorities are centered on forward-looking products in the medical device industry [1] - Dongxing Medical aims to maintain an innovation-driven approach to build technological advantages [1] - The company plans to advance its strategic implementation through both organic growth and external expansion, providing greater value returns to small and medium investors [1]

Core Viewpoint - Dongxing Medical (301290.SZ) is currently not involved in the design, research, or production of surgical robot-related products, focusing instead on innovative medical devices such as electric endoscopic staplers, ultrasonic scalpels, and tissue clips [1] Group 1 - The company's current research and development priorities are centered on forward-looking products in the medical device industry [1] - Dongxing Medical aims to maintain an innovation-driven approach to build technological advantages [1] - The company plans to advance its strategy through both internal development and external expansion, providing greater value returns to small and medium investors [1]